| DelveInsight The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based ...

The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies ...

MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active ...

The Georgia Dental Association (GDA) applauds the Georgia House of Representatives, the Georgia Senate, and Governor Brian Kemp for signing the Amended Fiscal Year (AFY) 2026 budget into law, securing ...

Nanalysis Scientific Corp. (the "Company" or "Nanalysis")   (FRA: 1N1) announces the Company's Board of Directors has granted 1,210,000 restricted share units ("RSUs") and 350,000 stock options ...

Question: I’ve been getting frequent heartburn over the past few months. At first it was from spicy food and now it’s from pretty much everything. I have been drinking bottles of Gaviscon after eating ...

Cancers affecting the digestive system are becoming increasingly common worldwide. Many of these cancers develop slowly and may not cause clear symptoms in the early stages. Because the signs often ...

LVEF (Left Ventricular Ejection Fraction): Percentage measure of how much blood the left ventricle pumps out with each ...

Good afternoon, and welcome to Cumberland Pharmaceuticals 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for 1 year ...

The Irvine, California-based company will now market its test to clinical labs throughout the UK for patient testing.

Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland ...

Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.